Compare Ecolab Inc. (ECL) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ecolab Inc. vs State Street SPDR S&P Biotech ETF — how do they compare? Ecolab Inc. trades at $281.36 (market cap $78.97B), while State Street SPDR S&P Biotech ETF trades at $149.93 (market cap $10.11B). The key difference: Ecolab Inc. is far larger — about 7.8× State Street SPDR S&P Biotech ETF's market cap, and Ecolab Inc. pays a 1.04% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ecolab Inc. for 90 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| ECL | XBI | |
|---|---|---|
Market Cap | $78.97B | $10.11B |
Volume | 974,947 | 12,903,266 |
Sector | Basic Materials | Broad Market / Factor |
52-Week High | $308.35 | $169.55 |
52-Week Low | $245.73 | $104.99 |
Typical Hold Time | 90 Days | 37 Days |
Enterprise Value | $87.75B | — |
Dividend Yield | 1.04% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ECL trades at $278.10, down 0.97% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported $16.08B in 2025 revenue, with a net income margin of 12.57% and strong profitability metrics. Recent news highlights its dividend aristocrat status and growth in high-tech segments, while institutional buying and insider purchases reflect confidence.
Outlook remains positive with a consensus price target of $326.38, implying 17% upside, supported by analyst buy ratings (78%). Risks include elevated valuation multiples and increased debt from the CoolIT acquisition. Earnings growth in high-tech and digital segments is a key catalyst, though cost fluctuations pose headwinds.
XBI trades at $150.23, down 0.44% on the day, with a bearish technical signal driven by moving averages and oscillators. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts. Recent news highlights sector optimism from cancer vaccine breakthroughs and improved capital access, though the ETF carries higher volatility than broader healthcare funds.
The outlook is mixed: strong sector tailwinds from innovation and consolidation support growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst sentiment is neutral with 100% hold ratings, suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Ecolab Inc.
Ecolab produces and markets cleaning and sanitation products for the hospitality, healthcare, and industrial markets. The firm is the global market share leader in this category with a wide array of products and services, including dish and laundry washing systems, pest control, and infection control products. The company has a strong hold on the U.S. market and is looking to increase its profitability abroad. Additionally, Ecolab serves customers in water, manufacturing, and life sciences end markets, selling customized solutions.
Read more on ECL →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
